<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Pharmaceutical Sciences</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C4E0ADBA-A8E0-4D61-B5FE-B033EF538BED"><gtr:id>C4E0ADBA-A8E0-4D61-B5FE-B033EF538BED</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:otherNames>Jayne</gtr:otherNames><gtr:surname>Lawrence</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FG061505%2F1"><gtr:id>6FCB4D1E-EAA4-4641-AD41-C1413D62641E</gtr:id><gtr:title>Nanoparticles for the Targeted Delivery of Therapeutic Agents to the Brain for the Treatment of Dementias.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/G061505/1</gtr:grantReference><gtr:abstractText>This project focuses on the development of nanotechnologies for the targeted delivery of novel therapies for Alzheimer's disease, the major cause of dementia in the elderly. The most common symptoms of dementias are gradual memory loss, confusion, and changes in personality, mood and behaviour. There are currently about 700,000 dementia patients in the UK and approximately 450,000 of those have Alzheimer's disease. There are no cures for dementias, only drugs that treat the symptoms and temporarily stabilize the disease progression so patients become more dependent on care. The cost of formal healthcare services (e.g., residential care, NHS support services) for dementia patients at 4Bn in 2002 are formidable, and expected to grow to 13Bn by 2031. However, when informal care contributions from families of patents are considered, estimated costs escalate to about 17Bn. There is a further economic and social toll from the impact of patient care on the careers of carers. Dementia is therefore a growing medical, social and economic problem for the UK and beyond. The current level of research activity into the understanding and treatment of dementias does not reflect the enormity of the growing challenge. Dementia is one of the major causes of disability in later life, contributing 11.2% of all years lived with disability over the age of 60, compared to 2.4% for cancer. Since 2002, however, only 1.4% of published research papers on disabilities concerned dementias, compared to 23.5% for cancers. Increased research funding and activity in dementias is therefore an urgent priority. We aim in this project to harness nanotechnologies for the design and delivery of new therapeutics for the treatment of Alzheimer's disease. Nanoparticles are formulations of synthetic, chemical components that self-assemble on mixing into particles of less than 100 nm. They can be used to package a variety of drugs, including genes, proteins and RNA molecules. The nanoparticle components that will be designed and synthesised will comprise novel peptides and lipids with smart properties, such as receptor targeting, stealth coatings, bioresponsive linkers for disassembly, and biocompatibility. The uptake of nanoparticles into the brain from the circulation is impeded by the blood brain barrier so we will optimise a method called convection enhanced delivery (CED). In CED the blood-brain barrier is physically bypassed by injecting reagents directly into the brain through a fine needle under constant pressure. CED has already been used to administer therapeutics, achieving widespread dispersal through the brain, but has not been optimised for nanoparticle delivery. The project combines basic studies into nanoparticle materials and biology of the brain in relation to CED, and more applied studies into nanoparticle formulation and CED-mediated dispersal studies using MRI. The output of this study will be a nanoparticle platform technology and delivery method compatible with a range of therapeutic options for Alzheimer's disease and other forms of dementia. The research team comprises scientific experts in chemistry, drug and nanoparticle formulations as well as clinical expertise in brain pathology, surgery and experimental clinical trials, and has the capabilities to succeed both in this project and a future Stage 2 therapeutic study into Alzheimer's disease. This new capability could transform the management of patients with dementias with enormous potential benefits to UK society and the economy.</gtr:abstractText><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>334089</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Molecules, Membranes and Medicines</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21DEC41C-2E67-4608-857C-4B373A3B1C1D</gtr:id><gtr:impact>Presented talk entitled 'Molecules, Membranes and Medicines: Where Are We Now?' (2015) to Science Technology Facilities Council Science Board, Swindon.</gtr:impact><gtr:outcomeId>56e070a95b71f7.15220336</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Deuteration Laboratory, Science Technology Facilities Council</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3F704243-A986-40F2-BD62-CCF3AE2B6838</gtr:id><gtr:impact>'Modelling the Cellular Fate of Gene Delivery Vehicles' (2015) ISIS Deuteration Facility Meeting, Oxford Spires Four Pillars, Oxford.</gtr:impact><gtr:outcomeId>56e071e04e8dd5.37619916</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation at PharmSci Fair, Prague, Czech Republic: Nanoparticles: their Potential in Delivering Therapeutic Molecules</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2BC7F5B0-3A20-441D-977F-0035D191B41F</gtr:id><gtr:impact>Presentation stimulated discussion and initiated a collaboration between ourselves and another speaker

Good feedback from the conference organisers regarding presentation</gtr:impact><gtr:outcomeId>546647f7380f46.63543367</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2015 British Science Festival Panel Debate</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F9EE662B-4B7B-4CC8-BD2E-24C944A94764</gtr:id><gtr:impact>Debate panel member at the 2015 British Science Festival, Bradford. Debate entitled 'Developing effective medicines in the modern age'.</gtr:impact><gtr:outcomeId>56e0700f4b67a0.05407145</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation at International Review of ISIS, Rutherford Appleton Laboratories, Didcot.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>82C3F55D-510D-43B9-998E-BB8DBB773997</gtr:id><gtr:impact>Presentation (entitled molecules, membranes and medicines) was for the purposes of the international review of ISIS and was well received by the panel as an example of international research performed at ISIS.

The presentation contributed to the excellent report the neutron facility at ISIS received from the review</gtr:impact><gtr:outcomeId>5466467d959896.51121113</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Drugs, genes and ethics - invited lecture (KIng's College London) to 14-16 year olds</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2E011BAF-E778-45C9-9204-0C6FB8270514</gtr:id><gtr:impact>Students commented that they enjoyed the presentation as it gave them a new insight into gene delivery

As yet unknown</gtr:impact><gtr:outcomeId>546642cdc163c3.13670358</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival, invited panelist in public debate about genetic medicine</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ABAA4786-9AD2-4631-82CD-44ED3AE4EC0B</gtr:id><gtr:impact>Our presentations as part of the debate sparked lots of questions and discussion

Invited to further debates</gtr:impact><gtr:outcomeId>5466421ca4f136.51179092</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation to Nanocolloid meeting, Amsterdam, Holland 'Rationale Design of Ternary Nanocomplexes for Gene Delivery'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AB1CCC34-1247-4D29-B980-C99995D82907</gtr:id><gtr:impact>Presentation stimulated considerable discussion afterwards and sparked at least two collaborations

Collaboration initiated between our group and that of Prof. Dganit Danino (Technicon, Isreal) around cryoelectron microscopy</gtr:impact><gtr:outcomeId>54664764aabdd5.77344744</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Formulation and Drug Delivery Congress</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>528BB7BB-65BA-4845-8DA0-4322EC330360</gtr:id><gtr:impact>'Rational Design of Complexes for Gene Delivery: A Case Study' (2015) Formulation and Drug Delivery Congress, London.</gtr:impact><gtr:outcomeId>56e07115412eb0.04124444</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation of Work at Interpharm - Joint Academic Industrial Meeting of Senior People in the Pharmaceutical Field</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95D802B3-2577-4CBD-B3BE-1D6B5BA67312</gtr:id><gtr:impact>Talk sparked interest from several industries and which resulted in joint research being undertaken

An opportunity to promote the research to a wide range of people in the pharmaceutical industry</gtr:impact><gtr:outcomeId>54664596875d64.84356114</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Swedish Chemical Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C2BDDC4A-853B-480D-831A-DACBB60D4EE4</gtr:id><gtr:impact>'Gene Delivery and the Interaction of DNA with Biomembranes: Neutron and X-Ray Scattering' (2014) Realizing Reformulation - A Symposium on Surface and Materials Chemistry, Swedish Chemical Society, Lund, Sweden.</gtr:impact><gtr:outcomeId>56e072548b3f10.01765975</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools visit (Bishop Wand School, Sunbury, Middlesex) RE lesson taken</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5332B6F0-6B62-47E2-B04A-636B286B1DAB</gtr:id><gtr:impact>Presentation greatly stimulated debate about gene therapy amongst the students (aged 14-16)

School reported back that the students has been challenged to think about things in a completely different way by the presentation</gtr:impact><gtr:outcomeId>546643c4989a03.95593513</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>76000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kings College London</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:fundingRef>King's China Overseas Research Student Awards</gtr:fundingRef><gtr:id>2C1D557B-6E3F-4C36-88C2-A324F98487DB</gtr:id><gtr:outcomeId>5ede486c5ede4880</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neutron beam time</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>ISIS</gtr:fundingOrg><gtr:fundingRef>RB1120431; RB1120399; RB1210318</gtr:fundingRef><gtr:id>0AC96604-504E-494E-A16F-40DC2470DB8C</gtr:id><gtr:outcomeId>5466405d879c24.26343675</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neutron beam time</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>ISIS</gtr:fundingOrg><gtr:fundingRef>ILL 8-02-577; ILL 8-02-579; RB1110429; RB1110440</gtr:fundingRef><gtr:id>A5628F06-DEF1-4D28-A16D-C28DB81C4768</gtr:id><gtr:outcomeId>54663f9291d789.47466528</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neutron beam time</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>ISIS</gtr:fundingOrg><gtr:fundingRef>RB920412</gtr:fundingRef><gtr:id>4B490908-6B6D-4EE0-918D-BE0F2FC0697E</gtr:id><gtr:outcomeId>546636854c1194.68696524</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neutron beam time</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>ISIS</gtr:fundingOrg><gtr:fundingRef>RB1220386; RB1220379</gtr:fundingRef><gtr:id>1B5FB67E-C319-47E0-9E20-55877EC881FC</gtr:id><gtr:outcomeId>546640e0992301.32579873</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>In addition to the data obtained being published in the form of scientific papers and presented in the form of talks and posters at major national and international conferences it has been used to inform a variety of work around public engagement (Cheltenham Festival of Science) and public information (web-sites). The information obtained from the study has been invaluable in preparing improved vehicles to delivery siRNA and DNA for the ultimate benefit of the patient. The information from the research is being used by researchers in the pharmaceutical industry to guide their formulations.</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>6829645B-74D2-474A-A507-46C9C61E5ED7</gtr:id><gtr:impactTypes><gtr:impactType>Cultural,Societal,Policy &amp; public services</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54661859cfa884.20272044</gtr:outcomeId><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The opportunity offered by gene therapy to treat diseases hitherto untreatable is enormous. Unfortunately it has proven very difficult to deliver genes to the required site in the body in a manner in which they can exert their therapeutic effect. The present study has been looking at ways of packaging the genes so that it will be possible to deliver them so that they can have maximum therapeutic benefit. To do this we have used a formulation composed of gene, lipid and DNA and have used a range of advanced techniques to study the formulations.</gtr:description><gtr:exploitationPathways>From a research perspective, valuable information has been gained as to how to formulate and characterise nanoparticles composed of DNA, lipid and peptide for the purposes of targeted gene therapy.
From a translational research perspective there is considerable information gained as to how to best prepare gene delivery vehicles for use in patients.</gtr:exploitationPathways><gtr:id>BE2E4D22-D935-4CE1-9DAE-59075D6CC0C5</gtr:id><gtr:outcomeId>5466177aeba548.24857346</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>55BF4113-4EDE-4918-9F75-D9B3D08AFDF7</gtr:id><gtr:title>Effect of the helper lipid DOPE on endosomal membrane integrity</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ba8bef5de849dc00baae8f6507966fb"><gtr:id>4ba8bef5de849dc00baae8f6507966fb</gtr:id><gtr:otherNames>Kudsiova L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>546630c0c7ba28.48090599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3364EF93-E57E-4534-AECD-62D7212A81A8</gtr:id><gtr:title>Non-viral, coated nanoparticles as vectors for gene therapy</gtr:title><gtr:parentPublicationTitle>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37bf4fb212772858781160506e3c42cf"><gtr:id>37bf4fb212772858781160506e3c42cf</gtr:id><gtr:otherNames>Campbell F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>54663210ddddd9.75114037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8BFCD7D-8A26-41C9-B467-33FECEB29383</gtr:id><gtr:title>Interaction of lipoplexes with early and late stage endosomal model membranes</gtr:title><gtr:parentPublicationTitle>Molecular Pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0885a70929542a895dc610c002073b0"><gtr:id>f0885a70929542a895dc610c002073b0</gtr:id><gtr:otherNames>Dabkowska AP</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>54663548e967c8.95709970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2E6DE50-3B91-45FD-BEA5-8E52BA13FEF8</gtr:id><gtr:title>Gene delivery using ternary lipopolyplexes incorporating branched cationic peptides: the role of Peptide sequence and branching.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e8d87031cc4ee32e771d815739336b"><gtr:id>90e8d87031cc4ee32e771d815739336b</gtr:id><gtr:otherNames>Welser K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>54663388584f63.40944039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C3EA82A-F609-4516-9912-2770CEB26190</gtr:id><gtr:title>Tailoring Nanocomplexes for the Delivery of Plasmid DNA or siRNA: The Role of Cationic Peptide Sequence and Branching</gtr:title><gtr:parentPublicationTitle>Biopolymers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e8d87031cc4ee32e771d815739336b"><gtr:id>90e8d87031cc4ee32e771d815739336b</gtr:id><gtr:otherNames>Welser K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54662ec655e430.77796425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A25452CD-4E16-4252-889B-36FD023ABC76</gtr:id><gtr:title>Comparing the delivery of anionic and cationic lipopolyplexes to the brain by convection enhanced delivery</gtr:title><gtr:parentPublicationTitle>International Journal of Pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ba8bef5de849dc00baae8f6507966fb"><gtr:id>4ba8bef5de849dc00baae8f6507966fb</gtr:id><gtr:otherNames>Kudsiova L</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>54663501decdf8.12373207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6F2FB33-3DD6-4504-9ECA-7CED9971F936</gtr:id><gtr:title>Tuning a gene delivery vector: the role of peptide sequence and peptide branching in delivering of DNA and siRNA to the cytoplasm</gtr:title><gtr:parentPublicationTitle>Biopolymers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e8d87031cc4ee32e771d815739336b"><gtr:id>90e8d87031cc4ee32e771d815739336b</gtr:id><gtr:otherNames>Welser K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>546632b6ab0a35.84400875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2D42005-7F11-42A2-8DCC-87C0540BA316</gtr:id><gtr:title>Polymer coated, targeted lipopolyplexes - a versatile non-viral gene vector</gtr:title><gtr:parentPublicationTitle>To be decided</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37bf4fb212772858781160506e3c42cf"><gtr:id>37bf4fb212772858781160506e3c42cf</gtr:id><gtr:otherNames>Campbell F</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>54663481aeb524.26654919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE687ABE-64BA-43C0-8E52-8DB8188E5B99</gtr:id><gtr:title>Targeted delivery of siRNA using ternary complexes containing branched cationic peptides: the role of peptide sequence and branching</gtr:title><gtr:parentPublicationTitle>Biomolecular Systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ba8bef5de849dc00baae8f6507966fb"><gtr:id>4ba8bef5de849dc00baae8f6507966fb</gtr:id><gtr:otherNames>Kudsiova L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>546633fc2d5293.31743732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25FC60A1-E21C-49A0-A443-BC474A45CF7F</gtr:id><gtr:title>Delivery of siRNA using ternary complexes containing branched cationic peptides: the role of peptide sequence, branching and targeting.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ba8bef5de849dc00baae8f6507966fb"><gtr:id>4ba8bef5de849dc00baae8f6507966fb</gtr:id><gtr:otherNames>Kudsiova L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>56e06e0e8f26a0.51117450</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G061505/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>